BOSTON, SAN FRANCISCO and LONDON, Jan. 6, 2011 /PRNewswire/ -- SV Life Sciences ("SVLS") today announced the promotion of Paul LaViolette to Partner. Mr. LaViolette joined SVLS in early 2009 as Venture Partner.
"Since joining SVLS, Paul has successfully applied his tremendous experience with large-scale medical technology businesses to our portfolio of development stage companies," said David Milne, SVLS Managing Partner. "In doing so, Paul has underscored a key component to the SVLS value proposition. Consistently, we have attracted highly talented healthcare operators and executives from the life sciences fields and made them long-term members of our investment team. I know I speak on behalf of the entire firm in congratulating Paul on his promotion."
At SVLS, Mr. LaViolette has attracted novel deal flow that has led to multiple new investments and investment options. He has assumed board and advisory roles for a number of existing SVLS portfolio companies including TransEnterix, CardioFocus, ValenTx, MindFrame and Altura Medical. In addition to these positions, he serves on the boards of Cameron Health, Conceptus, DC Devices, Direct Flow Medical, DJO Global, Thoratec, Trans 1, and the Medical Device Manufacturers Association (MDMA), giving him broad and ongoing exposure to the medical device and technology industries.
Mr. LaViolette has 30 years of global medical technology marketing and general management experience. Most recently, he was with Boston Scientific Corporation, where he served as COO, Group President, President-Cardiology and President-International. During his tenure, the Company grew revenues over 20 times. He also spearheaded over 20 acquisitions and led extensive product development, operations and worldwide commercial organizations. Prior to that, he held marketing and general management positions at CR Bard and various marketing roles at Kendall (Covidien). Mr. LaViolette has also served on the boards of Urologix